메뉴 건너뛰기




Volumn 28, Issue 12, 2014, Pages 2273-2275

Still no certainty about the role of upfront bortezomib among patients with AL amyloidosis

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; MELPHALAN; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

EID: 84925284470     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.271     Document Type: Editorial
Times cited : (4)

References (10)
  • 1
    • 84925286756 scopus 로고    scopus 로고
    • Melphalan and dexamethasone with or without bortezomib in newly-diagnosed AL amyloidosis: A matched case control study on 174 patients
    • Palladini G, Milani P, Foli A, Rosin MV, Basset M, Lavatelli F et al. Melphalan and dexamethasone with or without bortezomib in newly-diagnosed AL amyloidosis: a matched case control study on 174 patients. Leukemia 2014; 28: 2311-2316.
    • (2014) Leukemia , vol.28 , pp. 2311-2316
    • Palladini, G.1    Milani, P.2    Foli, A.3    Rosin, M.V.4    Basset, M.5    Lavatelli, F.6
  • 2
    • 84925286648 scopus 로고    scopus 로고
    • A matched comparison of cyclophophamide, bortezomib and dexamethasone (CVD) versus risk adapted cyclophosphamide, thalidomide, and dexamethasone (CTD) in AL amyloidosis
    • Venner CP, Gillmore JD, Sachchithanantham S, Mahmood S, Lane T, Forard D et al. A matched comparison of cyclophophamide, bortezomib and dexamethasone (CVD) versus risk adapted cyclophosphamide, thalidomide, and dexamethasone (CTD) in AL amyloidosis. Leukemia 2014; 28: 2304-2310
    • (2014) Leukemia , vol.28 , pp. 2304-2310
    • Venner, C.P.1    Gillmore, J.D.2    Sachchithanantham, S.3    Mahmood, S.4    Lane, T.5    Forard, D.6
  • 3
    • 84896718067 scopus 로고    scopus 로고
    • High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis
    • Dispenzieri A, Gertz MA, Kumar SK, Lacy MQ, Kyle RA, Saenger AK et al. High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. Heart 2014; 100: 383-388.
    • (2014) Heart , vol.100 , pp. 383-388
    • Dispenzieri, A.1    Gertz, M.A.2    Kumar, S.K.3    Lacy, M.Q.4    Kyle, R.A.5    Saenger, A.K.6
  • 4
    • 4444268210 scopus 로고    scopus 로고
    • Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
    • Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104: 1881-1887.
    • (2004) Blood , vol.104 , pp. 1881-1887
    • Dispenzieri, A.1    Gertz, M.A.2    Kyle, R.A.3    Lacy, M.Q.4    Burritt, M.F.5    Therneau, T.M.6
  • 5
    • 84879458198 scopus 로고    scopus 로고
    • A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis
    • Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013; 121: 3420-3427.
    • (2013) Blood , vol.121 , pp. 3420-3427
    • Wechalekar, A.D.1    Schonland, S.O.2    Kastritis, E.3    Gillmore, J.D.4    Dimopoulos, M.A.5    Lane, T.6
  • 7
    • 84860898706 scopus 로고    scopus 로고
    • Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
    • Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012; 119: 4391-4394.
    • (2012) Blood , vol.119 , pp. 4391-4394
    • Mikhael, J.R.1    Schuster, S.R.2    Jimenez-Zepeda, V.H.3    Bello, N.4    Spong, J.5    Reeder, C.B.6
  • 8
    • 84860897399 scopus 로고    scopus 로고
    • Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
    • Venner CP, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012; 119: 4387-4390.
    • (2012) Blood , vol.119 , pp. 4387-4390
    • Venner, C.P.1    Lane, T.2    Foard, D.3    Rannigan, L.4    Gibbs, S.D.5    Pinney, J.H.6
  • 9
    • 79960934028 scopus 로고    scopus 로고
    • Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: Results of a phase 1/2 study
    • Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Blade J et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood 2011; 118: 865-873.
    • (2011) Blood , vol.118 , pp. 865-873
    • Reece, D.E.1    Hegenbart, U.2    Sanchorawala, V.3    Merlini, G.4    Palladini, G.5    Blade, J.6
  • 10
    • 70349575412 scopus 로고    scopus 로고
    • Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: Results of a phase 1 dose-escalation study
    • Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 2009; 114: 1489-1497.
    • (2009) Blood , vol.114 , pp. 1489-1497
    • Reece, D.E.1    Sanchorawala, V.2    Hegenbart, U.3    Merlini, G.4    Palladini, G.5    Fermand, J.P.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.